Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−15.05 MXN
−1.56 B MXN
14.20 B MXN
About INTRA-CELLULAR THERAPIES, INC
Sector
Industry
CEO
Sharon L. Mates
Website
Headquarters
Bedminster
Founded
2002
FIGI
BBG019ZNXRT3
Intra-Cellular Therapies (ITI) develop new drugs for neuropsychiatric, neurologic diseases, and other Central Nervous System (CNS) disorders. The company integrates the work of medicinal scientists, pharmacologists, biologists, and clinical development scientists to create novel treatments. ITI's lead product, ITI-007, is a first-in-class 5-HT2A antagonist and dopamine receptor phosphoprotein modulator designed to treat schizophrenia with fewer side effects compared to current antipsychotic drugs. ITI has also developed CNSProfileTM, a technology platform that generates molecular signatures for drug compounds, providing insights into the intracellular actions of CNS drugs. This tool helps in drug discovery and development and is used to study the effects of brain-damaging nerve agents, leading to collaborations on antidotes for chemical warfare agents. Additionally, ITI is exploring new drug candidates for symptoms related to the transition from peri-menopause to post-menopause.
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of ITCI is 2,696.18 MXN — it has increased by 1.82% in the past 24 hours. Watch INTRA-CELLUAR THERAPIES INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange INTRA-CELLUAR THERAPIES INC stocks are traded under the ticker ITCI.
ITCI stock has risen by 1.82% compared to the previous week, the month change is a 2.67% rise, over the last year INTRA-CELLUAR THERAPIES INC has showed a 164.16% increase.
We've gathered analysts' opinions on INTRA-CELLUAR THERAPIES INC future price: according to them, ITCI price has a max estimate of 2,654.87 MXN and a min estimate of 2,654.87 MXN. Watch ITCI chart and read a more detailed INTRA-CELLUAR THERAPIES INC stock forecast: see what analysts think of INTRA-CELLUAR THERAPIES INC and suggest that you do with its stocks.
ITCI reached its all-time high on Apr 1, 2025 with the price of 2,696.18 MXN, and its all-time low was 939.32 MXN and was reached on Sep 27, 2023. View more price dynamics on ITCI chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ITCI stock is 1.79% volatile and has beta coefficient of 0.35. Track INTRA-CELLUAR THERAPIES INC stock price on the chart and check out the list of the most volatile stocks — is INTRA-CELLUAR THERAPIES INC there?
Yes, you can track INTRA-CELLUAR THERAPIES INC financials in yearly and quarterly reports right on TradingView.
INTRA-CELLUAR THERAPIES INC is going to release the next earnings report on May 13, 2025. Keep track of upcoming events with our Earnings Calendar.
ITCI earnings for the last quarter are −3.34 MXN per share, whereas the estimation was −1.54 MXN resulting in a −117.29% surprise. The estimated earnings for the next quarter are −1.71 MXN per share. See more details about INTRA-CELLUAR THERAPIES INC earnings.
INTRA-CELLUAR THERAPIES INC revenue for the last quarter amounts to 4.15 B MXN, despite the estimated figure of 4.03 B MXN. In the next quarter, revenue is expected to reach 4.21 B MXN.
ITCI net income for the last quarter is −352.04 M MXN, while the quarter before that showed −518.68 M MXN of net income which accounts for 32.13% change. Track more INTRA-CELLUAR THERAPIES INC financial stats to get the full picture.
No, ITCI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 15, 2025, the company has 860 employees. See our rating of the largest employees — is INTRA-CELLUAR THERAPIES INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. INTRA-CELLUAR THERAPIES INC EBITDA is −2.42 B MXN, and current EBITDA margin is −17.07%. See more stats in INTRA-CELLUAR THERAPIES INC financial statements.
Like other stocks, ITCI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade INTRA-CELLUAR THERAPIES INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So INTRA-CELLUAR THERAPIES INC technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating INTRA-CELLUAR THERAPIES INC stock shows the buy signal. See more of INTRA-CELLUAR THERAPIES INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.